RT Conference Proceedings
T1 Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
A1 Besse, B.
A1 Garcia Campelo, M. R.
A1 Cobo Dols, M. A.
A1 Quoix, E.
A1 Madroszyk, A.
A1 Felip, E.
A1 Cappuzzo, F.
A1 Denis, F.
A1 Hilgers, W.
A1 Romano, G.
A1 Debieuvre, D.
A1 Baldini, E.
A1 Galetta, D.
A1 Viteri, S.
A1 Phan, M.
A1 Schuette, W.
A1 Zer, A.
A1 Costantini, D.
A1 Dziadziuszko, R.
A1 Giaccone, G.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/26997
UL https://hdl.handle.net/10668/26997
LA en
DS RISalud
RD Apr 8, 2025